Final results of the PARERE Study
🩸 428 mCRC pts screened via liquid biopsy for anti-EGFR re-tx
🧬 >⅓ RAS and/or BRAF mut in ctDNA
❌ No OS diff (pani→rego vs rego→pani)
✅ Higher ORR, DCR & PFS with pani, regardless of sequence
doi.org/10.1016/j.anno…
The final results of the PARERE study by GONO Foundation concomitantly published on Annals of Oncology
#ESMO25 @myesmo.bsky.social
Open Access 👉 t.co/sTomWwT8Do
#ESMOGI25: Randomised #ClinicalTrials and real-world studies in #mCRC provide further evidence in favour of anti-EGFR rechallenge, particularly with a prolonged intertreatment interval.
Read more in the #ESMODailyReporter
🔗 ow.ly/ZfB450Wl2G8
First results from the PARERE trial by @FoundationGono
🩸RAS and BRAF ctDNA muts: >1/3 of mCRC patients eligible for anti-EGFR re-treatment
➡️ pani re-tx was associated with higher ORR, DCR, and longer PFS independently of the treatment sequencing
#ASCO25
@ascocancer.bsky.social
The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH
Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients @natrevclinonc.nature.com
Full Article 👉 rdcu.be/d0AHE
